BD Showcases the First Glass Pre-Fillable Syringe Validated for Delivery of Intravenous Drugs at Pharmapack 2019
BD HylokTM Designed for Secure and Safe Administration of Hyaluronic Acid and Intravenous Drugs
PARIS, February 6, 2019 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will present BD HylokTM, its new glass pre-fillable syringe for the administration of viscous solutions such as hyaluronic acid dermal fillers, at Europe's dedicated pharmaceutical packaging and drug delivery event, Pharmapack 2019, from February 6 to 7 in Paris, France.
Injection of hyaluronic acid exerts a high pressure on the syringe, due to the product’s viscosity.1 This high pressure may cause needle disconnection and syringe luer-lok adaptor (LLA) rotation, which may lead to leakage. A recent international survey found that 45 percent of dermatologists identified leakage as the main problem with hyaluronic acid syringes.2 High viscosity solutions have traditionally been administered by dermatologists using both glass and plastic syringes. Glass syringes are preferred by product manufacturers for their inertness and durability.3
BD Hylok is also the first glass pre-fillable syringe that is validated for delivery of intravenous drugs.4 It is compatible with main IV connectors and can be used for various indications where time, precision and dependability are essential.5
BD Hylok LLA is strongly affixed, using new bonding technology, and reduces the risk of LLA rotation or disconnection. Its LLA thread design provides a safe and robust needle and IV connection with needle as well as with IV connectors.
Peter Nolan, Worldwide President of BD Pharmaceutical Systems, said: “Our expanded portfolio of solutions on display during this year’s Pharmapack event, including the recent launch of BD Hylok, exemplifies BD’s ability to continuously innovate. By offering a stronger and better connection with needles and IV connectors, this new syringe has an array of medical uses and benefits that will suit multiple needs across the healthcare and medical aesthetics markets.”
BD Hylok is available in 1ml long format and additional sizes will be introduced in the future. BD Hylok comes with an extensive data package, to support product or drug manufacturers developmental, technical and registration efforts.
Visit the BD booth A30 at Pharmapack for an in-depth view of the company’s latest innovations in pre-fillable drug delivery systems. BD will host two educational Learning Labs during the event, the first ‘BD Hylok – An Innovative Glass Pre-Fillable Syringe for Hyaluronic Acid’, taking place at 3:50 p.m. – 4:20 p.m., February 6, will assess user needs in Hyaluronic Acid delivery and explore how the technology behind BD Hylok is designed to enhance the user experience. The second, ‘The Value of a Robust System Integration for Advanced Drug Delivery Solutions’, taking place at 3:50 p.m. – 4:20 p.m., February 7, will cover the aspects of safe and effective drug delivery for patients and the importance of robust system integration in autoinjectors.
At Pharmapack’s Innovation Gallery, an exhibition which showcases the most innovative products from the pharmaceutical packaging and drug delivery industry, BD will present novel products including BD Hylok and BD Intevia, a uniquely designed disposable autoinjector for high-viscous drug delivery.
More than 70 percent of the top 100 global pharmaceutical companies use BD Medical-Pharmaceutical Systems’ pre-fillable drug-delivery systems for a variety of therapeutic applications.6 With an extensive portfolio of pre-fillable syringes, self-injection systems, safety and shielding solutions, BD’s products are designed to protect, package and deliver drug therapies, and to maximize healthcare worker and patient safety.
For more information on BD Hylok please visit: http://drugdeliverysystems.bd.com/products/prefillable-syringe-systems/acute-care-and-specialty-syringes/hylok-glass-pre-fillable-syringe
BD is one of the largest global medical technology companies and is advancing healthcare by improving medical discovery, diagnostics and care delivery. The company supports the heroes that work on the frontline by developing innovative technology, services and solutions, to advance clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.
For further information:
Matt Coppola Monique N. Dolecki
BD Public Relations BD Investor Relations